Ferroportin 1 but not hephaestin contributes to iron accumulation in a cell model of Parkinson's disease

Free Radical Biology and Medicine

Volumn 48, Issue 2, 2010, Pages 332-341

  Song, Ning ^a   Wang, Jun ^a   Jiang, Hong ^a   Xie, Junxia ^a  

^a Medical College   (China)

Author keywords

6 Hydroxydopamine; Ferroportin 1; Free radicals; Hephaestin; Iron; Oxidative stress; Parkinson disease

Indexed keywords

FERROPORTIN 1; FREE RADICAL; HEPHAESTIN; IRON; OXIDOPAMINE; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL MODEL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOWN REGULATION; EMBRYO; GENE SILENCING; IRON OVERLOAD; IRON TRANSPORT; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; UPREGULATION;

ANIMALS; CATION TRANSPORT PROTEINS; CELL LINE; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HUMANS; IRON; IRON REGULATORY PROTEIN 1; IRON REGULATORY PROTEIN 2; MEMBRANE PROTEINS; MESENCEPHALON; NEURONS; OXIDATIVE STRESS; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, WISTAR; RNA, SMALL INTERFERING;

ANIMALIA;

EID: 72649090521     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2009.11.004     Document Type: Article

References (59)

1. Olanow C.W. The pathogenesis of cell death in Parkinson's disease-2007. Mov. Disord. 22 Suppl. 17 (2007) S335-S342
2. Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci. 30 (2007) 244-250
3. Berg D., and Hochstrasser H. Iron metabolism in Parkinsonian syndromes. Mov. Disord. 21 (2006) 1299-1310
4. Curtis A.R., Fey C., Morris C.M., Bindoff L.A., Ince P.G., Chinnery P.F., Coulthard A., Jackson M.J., Jackson A.P., McHale D.P., Hay D., Barker W.A., Markham A.F., Bates D., Curtis A., and Burn J. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat. Genet. 28 (2001) 350-354
5. Gotz M.E., Double K., Gerlach M., Youdim M.B., and Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. Ann. N. Y. Acad. Sci. 1012 (2004) 193-208
6. Martin W.R., Wieler M., and Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 70 (2008) 1411-1417
7. Oakley A.E., Collingwood J.F., Dobson J., Love G., Perrott H.R., Edwardson J.A., Elstner M., and Morris C.M. Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology 68 (2007) 1820-1825
8. Perry G., Sayre L.M., Atwood C.S., Castellani R.J., Cash A.D., Rottkamp C.A., and Smith M.A. The role of iron and copper in the aetiology of neurodegenerative disorders: therapeutic implications. CNS Drugs 16 (2002) 339-352
9. Zecca L., Youdim M.B., Riederer P., Connor J.R., and Crichton R.R. Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 5 (2004) 863-873
10. Salazar J., Mena N., Hunot S., Prigent A., Alvarez-Fischer D., Arredondo M., Duyckaerts C., Sazdovitch V., Zhao L., Garrick L.M., Nunez M.T., Garrick M.D., Raisman-Vozari R., and Hirsch E.C. Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc. Natl. Acad. Sci. USA 105 (2008) 18578-18583
11. Shachar D.B., Kahana N., Kampel V., Warshawsky A., and Youdim M.B. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats. Neuropharmacology 46 (2004) 254-263
12. Tarohda T., Ishida Y., Kawai K., Yamamoto M., and Amano R. Regional distributions of manganese, iron, copper, and zinc in the brains of 6-hydroxydopamine-induced parkinsonian rats. Anal. Bioanal. Chem. 383 (2005) 224-234
13. Wang J., Jiang H., and Xie J.X. Time dependent effects of 6-OHDA lesions on iron level and neuronal loss in rat nigrostriatal system. Neurochem. Res. 29 (2004) 2239-2243
14. Zhang X., Xie W., Qu S., Pan T., Wang X., and Le W. Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration. Biochem. Biophys. Res. Commun. 333 (2005) 544-549
15. Zhu W., Xie W., Pan T., Xu P., Fridkin M., Zheng H., Jankovic J., Youdim M.B., and Le W. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J. 21 (2007) 3835-3844
16. Mandel S., Grunblatt E., Riederer P., Gerlach M., Levites Y., and Youdim M.B. Neuroprotective strategies in Parkinson's disease: an update on progress. CNS Drugs 17 (2003) 729-762
17. Jiang H., Qian Z.M., and Xie J.X. [Increased DMT1 expression and iron content in MPTP-treated C57BL/6 mice]. Sheng Li Xue Bao 55 (2003) 571-576
18. Song N., Jiang H., Wang J., and Xie J.X. Divalent metal transporter 1 up-regulation is involved in the 6-hydroxydopamine-induced ferrous iron influx. J. Neurosci. Res. 85 (2007) 3118-3126
19. Xu H.M., Jiang H., Wang J., Luo B., and Xie J.X. Over-expressed human divalent metal transporter 1 is involved in iron accumulation in MES23.5 cells. Neurochem. Int. 52 (2008) 1044-1051
20. Zhang S., Wang J., Song N., Xie J., and Jiang H. Up-regulation of divalent metal transporter 1 is involved in 1-methyl-4-phenylpyridinium (MPP(+))-induced apoptosis in MES23.5 cells. Neurobiol. Aging 30 (2009) 1466-1476
21. Abboud S., and Haile D.J. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J. Biol. Chem. 275 (2000) 19906-19912
22. Donovan A., Brownlie A., Zhou Y., Shepard J., Pratt S.J., Moynihan J., Paw B.H., Drejer A., Barut B., Zapata A., Law T.C., Brugnara C., Lux S.E., Pinkus G.S., Pinkus J.L., Kingsley P.D., Palis J., Fleming M.D., Andrews N.C., and Zon L.I. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 403 (2000) 776-781
23. McKie A.T., Marciani P., Rolfs A., Brennan K., Wehr K., Barrow D., Miret S., Bomford A., Peters T.J., Farzaneh F., Hediger M.A., Hentze M.W., and Simpson R.J. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol. Cell 5 (2000) 299-309
24. Anderson G.J., Frazer D.M., McKie A.T., and Vulpe C.D. The ceruloplasmin homolog hephaestin and the control of intestinal iron absorption. Blood Cells Mol. Dis. 29 (2002) 367-375
25. Vulpe C.D., Kuo Y.M., Murphy T.L., Cowley L., Askwith C., Libina N., Gitschier J., and Anderson G.J. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat. Genet. 21 (1999) 195-199
26. Burdo J.R., Menzies S.L., Simpson I.A., Garrick L.M., Garrick M.D., Dolan K.G., Haile D.J., Beard J.L., and Connor J.R. Distribution of divalent metal transporter 1 and metal transport protein 1 in the normal and Belgrade rat. J. Neurosci. Res. 66 (2001) 1198-1207
27. Jiang D.H., Ke Y., Cheng Y.Z., Ho K.P., and Qian Z.M. Distribution of ferroportin1 protein in different regions of developing rat brain. Dev. Neurosci. 24 (2002) 94-98
28. Qian Z.M., Chang Y.Z., Zhu L., Yang L., Du J.R., Ho K.P., Wang Q., Li L.Z., Wang C.Y., Ge X., Jing N.L., Li L., and Ke Y. Development and iron-dependent expression of hephaestin in different brain regions of rats. J. Cell. Biochem. 102 (2007) 1225-1233
29. Wang J., Jiang H., and Xie J.X. Ferroportin1 and hephaestin are involved in the nigral iron accumulation of 6-OHDA-lesioned rats. Eur. J. Neurosci. 25 (2007) 2766-2772
30. Crawford Jr. G.D., Le W.D., Smith R.G., Xie W.J., Stefani E., and Appel S.H. A novel N18TG2 × mesencephalon cell hybrid expresses properties that suggest a dopaminergic cell line of substantia nigra origin. J. Neurosci. 12 (1992) 3392-3398
31. McNaught K.S., Mytilineou C., Jnobaptiste R., Yabut J., Shashidharan P., Jennert P., and Olanow C.W. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J. Neurochem. 81 (2002) 301-306
32. Pardo B., Paino C.L., Casarejos M.J., and Mena M.A. Neuronal-enriched cultures from embryonic rat ventral mesencephalon for pharmacological studies of dopamine neurons. Brain Res. Brain Res. Protoc. 1 (1997) 127-132
33. Liu X., Fan X.L., Zhao Y., Luo G.R., Li X.P., Li R., and Le W.D. Estrogen provides neuroprotection against activated microglia-induced dopaminergic neuronal injury through both estrogen receptor-alpha and estrogen receptor-beta in microglia. J. Neurosci. Res. 81 (2005) 653-665
34. Breuer W., Epsztejn S., and Cabantchik Z.I. Iron acquired from transferrin by K562 cells is delivered into a cytoplasmic pool of chelatable iron(II). J. Biol. Chem. 270 (1995) 24209-24215
35. Tenopoulou M., Doulias P.T., Barbouti A., Brunk U., and Galaris D. Role of compartmentalized redox-active iron in hydrogen peroxide-induced DNA damage and apoptosis. Biochem. J. 387 (2005) 703-710
36. Nemeth E., Tuttle M.S., Powelson J., Vaughn M.B., Donovan A., Ward D.M., Ganz T., and Kaplan J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306 (2004) 2090-2093
37. Han O., and Kim E.Y. Colocalization of ferroportin-1 with hephaestin on the basolateral membrane of human intestinal absorptive cells. J. Cell. Biochem. 101 (2007) 1000-1010
38. Ganz T. Cellular iron: ferroportin is the only way out. Cell Metab. 1 (2005) 155-157
39. De Domenico I., Ward D.M., Nemeth E., Vaughn M.B., Musci G., Ganz T., and Kaplan J. The molecular basis of ferroportin-linked hemochromatosis. Proc. Natl. Acad. Sci. USA 102 (2005) 8955-8960
40. Donovan A., Lima C.A., Pinkus J.L., Pinkus G.S., Zon L.I., Robine S., and Andrews N.C. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab. 1 (2005) 191-200
41. Galli A., Bergamaschi G., Recalde H., Biasiotto G., Santambrogio P., Boggi S., Levi S., Arosio P., and Cazzola M. Ferroportin gene silencing induces iron retention and enhances ferritin synthesis in human macrophages. Br. J. Haematol. 127 (2004) 598-603
42. Jeong S.Y., and David S. Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system. J. Biol. Chem. 278 (2003) 27144-27148
43. Hahn P., Qian Y., Dentchev T., Chen L., Beard J., Harris Z.L., and Dunaief J.L. Disruption of ceruloplasmin and hephaestin in mice causes retinal iron overload and retinal degeneration with features of age-related macular degeneration. Proc. Natl. Acad. Sci. USA 101 (2004) 13850-13855
44. Hadziahmetovic M., Dentchev T., Song Y., Haddad N., He X., Hahn P., Pratico D., Wen R., Harris Z.L., Lambris J.D., Beard J., and Dunaief J.L. Ceruloplasmin/hephaestin knockout mice model morphologic and molecular features of AMD. Invest. Ophthalmol. Visual Sci. 49 (2008) 2728-2736
45. Deumens R., Blokland A., and Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp. Neurol. 175 (2002) 303-317
46. Kaariainen T.M., Piltonen M., Ossola B., Kekki H., Lehtonen S., Nenonen T., Lecklin A., Raasmaja A., and Mannisto P.T. Lack of robust protective effect of quercetin in two types of 6-hydroxydopamine-induced parkinsonian models in rats and dopaminergic cell cultures. Brain Res. 1203 (2008) 149-159
47. Weng Z., Signore A.P., Gao Y., Wang S., Zhang F., Hastings T., Yin X.M., and Chen J. Leptin protects against 6-hydroxydopamine-induced dopaminergic cell death via mitogen-activated protein kinase signaling. J. Biol. Chem. 282 (2007) 34479-34491
48. Lymboussaki A., Pignatti E., Montosi G., Garuti C., Haile D.J., and Pietrangelo A. The role of the iron responsive element in the control of ferroportin1/IREG1/MTP1 gene expression. J. Hepatol. 39 (2003) 710-715
49. Frazer D.M., Vulpe C.D., McKie A.T., Wilkins S.J., Trinder D., Cleghorn G.J., and Anderson G.J. Cloning and gastrointestinal expression of rat hephaestin: relationship to other iron transport proteins. Am. J. Physiol. Gastrointest. Liver Physiol. 281 (2001) G931-G939
50. Gleeson F., Ryan E., Barrett S., Russell J., Kelleher B., and Crowe J. Duodenal Dcytb and hephaestin mRNA expression are not significantly modulated by variations in body iron homeostasis. Blood Cells Mol. Dis. 35 (2005) 303-308
51. Hentze M.W., and Kuhn L.C. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc. Natl. Acad. Sci. USA 93 (1996) 8175-8182
52. 2) control mammalian iron metabolism by different pathways. Mol. Cell. Biol. 16 (1996) 3781-3788
53. Hanrott K., Gudmunsen L., O'Neill M.J., and Wonnacott S. 6-Hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cdelta. J. Biol. Chem. 281 (2006) 5373-5382
54. Nunez-Millacura C., Tapia V., Munoz P., Maccioni R.B., and Nunez M.T. An oxidative stress-mediated positive-feedback iron uptake loop in neuronal cells. J. Neurochem. 82 (2002) 240-248
55. Regan R.F., Chen M., Li Z., Zhang X., Benvenisti-Zarom L., and Chen-Roetling J. Neurons lacking iron regulatory protein-2 are highly resistant to the toxicity of hemoglobin. Neurobiol. Dis. 31 (2008) 242-249
56. Regan R.F., Li Z., Chen M., Zhang X., and Chen-Roetling J. Iron regulatory proteins increase neuronal vulnerability to hydrogen peroxide. Biochem. Biophys. Res. Commun. 375 (2008) 6-10
57. Niles B.J., Clegg M.S., Hanna L.A., Chou S.S., Momma T.Y., Hong H., and Keen C.L. Zinc deficiency-induced iron accumulation, a consequence of alterations in iron regulatory protein-binding activity, iron transporters, and iron storage proteins. J. Biol. Chem. 283 (2008) 5168-5177
58. Blum D., Torch S., Lambeng N., Nissou M., Benabid A.L., Sadoul R., and Verna J.M. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 65 (2001) 135-172
59. Jiang, H.; Song, N.; Xu, H. M.; Zhang, S. Z.; Wang, J.; Xie, J. X. Up-regulation of divalent metal transporter 1 in 6-hydroxydopamine intoxication is IRE/IRP dependent. Cell Res. in press; 2009.